These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 13108861)

  • 1. Immunization against brucella infection. I. Isolation and characterization of a streptomycin-dependent mutant.
    HERZBERG M; ELBERG S
    J Bacteriol; 1953 Nov; 66(5):585-99. PubMed ID: 13108861
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunization against brucella infection. II. Effectiveness of a streptomycin-dependent strain of brucella melitensis.
    HERZBERG M; ELBERG SS; MEYER KF
    J Bacteriol; 1953 Nov; 66(5):600-5. PubMed ID: 13108862
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunization against Brucella infection. VI. Immunity conferred on goats by a nondependent mutant from a streptomycin-dependent mutant strain of Brucella melitensis.
    ELBERG SS; FAUNCE K
    J Bacteriol; 1957 Feb; 73(2):211-7. PubMed ID: 13416171
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunization against Brucella infection. V. Histopathologic appraisal of immunity induced in mice by a streptomycin-dependent mutant of Brucella melitensis.
    ELBERG SS; STEINER PE; DOLL JP
    Am J Pathol; 1955; 31(6):1065-75. PubMed ID: 13268611
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunization against Brucella infection. IV. Response of monkeys to injection of a streptomycin-dependent strain of Brucella melitensis.
    ELBERG SS; HENDERSON DW; HERZBERG M; PEACOCK S
    J Bacteriol; 1955 Jun; 69(6):643-8. PubMed ID: 14392120
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunization against brucella infection. III. Response of mice and guinea pigs to injection of viable and nonviable suspensions of a streptomycin-dependent mutant of Brucella malitensis.
    HERZBERG M; ELBERG SS
    J Bacteriol; 1955 Apr; 69(4):432-5. PubMed ID: 14367297
    [No Abstract]   [Full Text] [Related]  

  • 7. The Brucella melitensis M5-90ΔmanB live vaccine candidate is safer than M5-90 and confers protection against wild-type challenge in BALB/c mice.
    Zhang J; Yin S; Yi D; Zhang H; Li Z; Guo F; Chen C; Fang W; Wang J
    Microb Pathog; 2017 Nov; 112():148-155. PubMed ID: 28916316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved influenza viral vector based Brucella abortus vaccine induces robust B and T-cell responses and protection against Brucella melitensis infection in pregnant sheep and goats.
    Mailybayeva A; Yespembetov B; Ryskeldinova S; Zinina N; Sansyzbay A; Renukaradhya GJ; Petrovsky N; Tabynov K
    PLoS One; 2017; 12(10):e0186484. PubMed ID: 29023541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control of Brucella melitensis infection in a large camel herd in Saudi Arabia using antibiotherapy and vaccination with Rev. 1 vaccine.
    Radwan AI; Bekairi SI; Mukayel AA; al-Bokmy AM; Prasad PV; Azar FN; Coloyan ER
    Rev Sci Tech; 1995 Sep; 14(3):719-32. PubMed ID: 8593404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [ATTEMPT AT VACCINATION OF GUINEA PIGS AGAINST BRUCELLA MELITENSIS BY MEANS OF A KILLED VACCINE].
    QUATREFAGES H; CARRERE L; PETITDIDIER M
    Ann Inst Pasteur (Paris); 1965 Aug; 109():305-9. PubMed ID: 14336050
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunization against Brucella infection. 8. The response of Cynomolgus philippinensis, guinea-pigs and pregnant goats to injection by the Rev I strain of Brucella melitensis.
    ELBERG SS; FAUNCE WK
    Bull World Health Organ; 1962; 26(3):421-36. PubMed ID: 13889789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility of
    Shevtsov A; Syzdykov M; Kuznetsov A; Shustov A; Shevtsova E; Berdimuratova K; Mukanov K; Ramankulov Y
    Antimicrob Resist Infect Control; 2017; 6():130. PubMed ID: 29299304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection.
    Cassataro J; Estein SM; Pasquevich KA; Velikovsky CA; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH
    Infect Immun; 2005 Dec; 73(12):8079-88. PubMed ID: 16299302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with Brucella abortus rough mutant RB51 protects BALB/c mice against virulent strains of Brucella abortus, Brucella melitensis, and Brucella ovis.
    Jiménez de Bagüés MP; Elzer PH; Jones SM; Blasco JM; Enright FM; Schurig GG; Winter AJ
    Infect Immun; 1994 Nov; 62(11):4990-6. PubMed ID: 7927779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Brucella melitensis M5-90 wboA deletion strain is attenuated and enhances vaccine efficacy.
    Li ZQ; Shi JX; Fu WD; Zhang Y; Zhang J; Wang Z; Li TS; Chen CF; Guo F; Zhang H
    Mol Immunol; 2015 Aug; 66(2):276-83. PubMed ID: 25899866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IMMUNIZATION AGAINST BRUCELLA INFECTION. 10. THE RELATIVE IMMUNOGENICITY OF BRUCELLA ABORTUS STRAIN 19-BA AND BRUCELLA MELITENSIS STRAIN REV I IN CYNOMOLGUS PHILIPPINENSIS.
    ELBERG SS; FAUNCE WK
    Bull World Health Organ; 1964; 30(5):693-9. PubMed ID: 14196815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Potentiation of the antibiotic properties of streptomycin regarding Brucella melitensis by a new antibiotic, oxamycin].
    LEON AP; DE LOURDES TRONCOSO M
    Rev Inst Salubr Enferm Trop; 1955 Jun; 15(2):57-72. PubMed ID: 13281113
    [No Abstract]   [Full Text] [Related]  

  • 18. Subcutaneous immunization with a novel immunogenic candidate (urease) confers protection against Brucella abortus and Brucella melitensis infections.
    Abkar M; Amani J; Sahebghadam Lotfi A; Nikbakht Brujeni G; Alamian S; Kamali M
    APMIS; 2015 Aug; 123(8):667-75. PubMed ID: 25939375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16M.
    Izadjoo MJ; Bhattacharjee AK; Paranavitana CM; Hadfield TL; Hoover DL
    Infect Immun; 2004 Jul; 72(7):4031-9. PubMed ID: 15213148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine.
    Bhattacharjee AK; Izadjoo MJ; Zollinger WD; Nikolich MP; Hoover DL
    Infect Immun; 2006 Oct; 74(10):5820-5. PubMed ID: 16988260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.